Nikki’s research group has also shown that cancer cells with loss of PPP2R2A are highly sensitive to two specific classes of anticancer drugs: PARP inhibitors, and PP2A activating drugs. This project will test whether tumours with PPP2R2A loss will respond to chemotherapy treatment using one, or a combination, of PARP inhibitor and PP2A activating drug.
Previous research has shown that the PPP2R2A gene is ‘lost’ or ‘switched off’, in up to half of all breast cancer, prostate cancer, ovarian cancer, lung cancer, and colon cancer patients.